Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

Table 1 Characteristics of patients with NVG

	Injection Group	Control Group	P
Total Patients	21	22
Gender			0.45
Male	10	13
Female	11	9
Age	60.1 ± 13.8 (32–81)	58.6 ± 17.3 (28–81)	0.76
Diagnosis			0.90
CRVO	8	7
BRVO	2	2
DR	11	13
Baseline IOP (mm Hg)	46.4 ± 13.3 (24.5–76.0)	45.0 ± 14.9 (23.5–78.5)	0.74
Prior intravitreal injection	0	0
NVI/NVA Degree			0.90
NVI only	3	2
NVI&NVA (Open-angle)	5	4
NVI&NVA (partial Closed-angle)	2	3
NVI&NVA (Closed-angle)	11	13
PRP before			0.55
none	12	9
Incomplete	6	8
complete	3	5
BCVA (LogMAR)	1.1 ± 0.4 (0.3–1.6)	1.2 ± 0.4 (0.4–1.6)	0.65
Pre-medications	2.5 ± 0.5 (2–3)	2.6 ± 0.5 (2–3)	0.66

Note: The difference in gender was compared between the two groups using the chi-square test, the difference in NVI/NVA degree was compared using two-tailed Fisher’s exact test, and the differences in diagnosis and PRP before were compared using the corrected chi-square test. Differences in age, IOP, BCVA and anti-glaucoma medications were compared using the t test

ISSN: 1471-2415